US 12,239,662 B2
Compositions for inhibiting anaerobic microorganisms
Larry D. Sutton, Platte City, MO (US)
Assigned to LPOXY Therapeutics, Inc., Platte City, MO (US)
Filed by LPOXY THERAPEUTICS, INC, Platte City, MO (US)
Filed on Jun. 21, 2024, as Appl. No. 18/750,994.
Application 18/750,994 is a continuation of application No. 18/169,061, filed on Feb. 14, 2023, granted, now 12,053,488.
Application 18/169,061 is a continuation of application No. 17/650,055, filed on Feb. 4, 2022, granted, now 11,944,641, issued on Apr. 2, 2024.
Application 17/650,055 is a continuation of application No. 17/304,447, filed on Jun. 21, 2021, granted, now 11,883,428, issued on Jan. 30, 2024.
Application 17/304,447 is a continuation of application No. PCT/US2021/025217, filed on Mar. 31, 2021.
Claims priority of provisional application 63/005,121, filed on Apr. 3, 2020.
Prior Publication US 2024/0415881 A1, Dec. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 33/40 (2006.01); C12N 9/08 (2006.01)
CPC A61K 33/40 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/4808 (2013.01); C12N 9/0065 (2013.01); C12Y 111/01006 (2013.01)] 17 Claims
 
1. A composition for treating a Clostridioides difficile infection, comprising:
an oxygen prodrug;
a catalyst that increases the rate of conversion of the oxygen prodrug to oxygen at a target site in an intestine of a subject;
a first controlled release coating encasing the oxygen prodrug, a second controlled release coating encasing the catalyst and the encased oxygen prodrug, a porous membrane that encapsulates the catalyst and the encased oxygen prodrug, and an enteric coating surrounding the composition,
wherein the porous membrane has a functional pore size that is smaller than an actual pore size,
wherein the porous membrane controls diffusion of the catalyst across said membrane, and
wherein, when at the target site in the intestine of the subject, the catalyst catalyzes conversion of the oxygen prodrug to generate oxygen and create an aerobic environment at the target site in the intestine of the subject sufficient to treat the subject suffering from the Clostridioides difficile infection by reducing a population of Clostridioides difficile, wherein the aerobic environment at the target site in the intestine of the subject comprises a concentration of 2-5% oxygen for 24 hours or more.